Original Posting:
https://pubmed.ncbi.nlm.nih.gov/40631423
This summary draws from the second source provided, titled “One Year in Review 2025,” which provides a modern update on the classification, clinical challenges, and treatment of Osteogenesis Imperfecta (OI).
A Modern Look at OI: Classification and New Discoveries
The sources explain that OI is primarily a genetic disorder affecting type I collagen, which makes up 90% of our bone matrix. While we have known about the “Sillence types” (1–5) for decades, doctors are moving toward a “dyadic nosology.” This means they now use a two-part system that combines a patient’s clinical symptoms (like bone fragility or blue sclera) with their genetic mutation (types I–XXIII). This change is necessary because people in the same family with the same mutation can have very different levels of severity.
Broadening the Focus: It’s More Than Just Bones
New research from 2024–2025 highlights that OI affects the entire body, not just the skeleton:
• Hearing Loss: A large study found that hearing loss is much more common in OI patients (17%) than in the general population (4%) and typically starts about 16 years earlier, often around age 42.
• Heart Health: While there are no formal guidelines yet, researchers suggest all OI patients get a baseline echocardiogram to check for heart valve issues, especially if they have joint hypermobility.
• Dental Issues: Between 20% and 48% of patients have Dentinogenesis Imperfecta (fragile, discolored teeth), and many deal with “Class III” malocclusions (underbites).
• Eye Health: To help doctors more accurately identify “blue sclera,” a new computer-based procedure called “BLUES” has been developed to objectively measure the color of the eye.
The Evolving Treatment Landscape
For years, bisphosphonates like neridronate and zoledronate have been the “cornerstone” of treatment to improve bone density. However, the sources point to an exciting new era of targeted therapies:
• Denosumab: This is a strong alternative to bisphosphonates, though doctors must watch for rebound high calcium levels in children.
• Setrusumab: A new antibody that has shown great promise in adults by significantly increasing bone density in the spine and hips.
• Future Frontiers: Trials are currently exploring stem cell transplants (MSC) for infants and new antibodies that target specific growth factors (TGF-β) to improve bone quality.
——————————————————————————–
What this may mean for OI Patients
For those living with OI, this recent research signals a shift toward “whole-body” care. It suggests that managing the condition is no longer just about preventing fractures; it now requires regular hearing tests, dental checkups, and heart screenings started much earlier in life than for the average person. The move toward a more detailed classification system means your doctor can provide a more personalized roadmap for your health. Most importantly, the arrival of new drugs like setrusumab and the study of stem cell therapies offer hope for treatments that don’t just “patch” the bone but actually improve its underlying structure and strength.